Acadian Asset Management LLC Raises Stock Holdings in Design Therapeutics, Inc. $DSGN

Key Points

• Acadian Asset Management LLC increased its stake in Design Therapeutics by 11.2%, acquiring an additional 63,349 shares, bringing its total to 630,953 shares valued at approximately $2.43 million.
• The company missed analysts' earnings estimates for the last quarter, reporting a loss of ($0.34) earnings per share, compared to the consensus estimate of ($0.32).
• Design Therapeutics has a market capitalization of $333.73 million and its stock has fluctuated between a low of $2.60 and a high of $7.77 over the past year.

Acadian Asset Management LLC raised its position in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 11.2% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 630,953 shares of the company's stock after acquiring an additional 63,349 shares during the quarter. Acadian Asset Management LLC owned approximately 1.11% of Design Therapeutics worth $2,434,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of DSGN. Velan Capital Investment Management LP purchased a new position in Design Therapeutics during the 1st quarter valued at approximately $54,000. Jane Street Group LLC purchased a new stake in shares of Design Therapeutics in the 1st quarter worth $70,000. ProShare Advisors LLC purchased a new stake in shares of Design Therapeutics in the 4th quarter worth $71,000. American Century Companies Inc. lifted its holdings in shares of Design Therapeutics by 13.5% in the 1st quarter. American Century Companies Inc. now owns 44,415 shares of the company's stock worth $171,000 after buying an additional 5,300 shares during the period. Finally, Palumbo Wealth Management LLC raised its position in shares of Design Therapeutics by 6.5% in the 1st quarter. Palumbo Wealth Management LLC now owns 58,278 shares of the company's stock worth $225,000 after acquiring an additional 3,582 shares in the last quarter. Hedge funds and other institutional investors own 56.64% of the company's stock.

Design Therapeutics Trading Down 3.2%

Shares of DSGN traded down $0.20 during trading hours on Friday, hitting $6.05. The company had a trading volume of 979,409 shares, compared to its average volume of 162,062. The company's fifty day moving average price is $5.00 and its two-hundred day moving average price is $4.29. Design Therapeutics, Inc. has a one year low of $2.60 and a one year high of $7.77. The company has a market capitalization of $344.55 million, a PE ratio of -5.40 and a beta of 1.61.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.02). Analysts forecast that Design Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Design Therapeutics Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.